Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Bayer Receives FDA Approval for BETACONNECT - First and Only Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment
Building a better sphingosine kinase-1 inhibitor.
Sleep Disorders and Multiple Sclerosis: A Clinical and Polysomnography Study.
Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis.
CD4 cell response to interval therapy with natalizumab.
A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C.
miRNA in multiple sclerosis: search for novel biomarkers.
Immunopathology of multiple sclerosis.
Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.
Submembranous cytoskeletons stabilize nodes of Ranvier.
Mesenchymal stem cells as treatment for MS - progress to date.
The site of production of superoxide radical in mitochondrial Complex I is not a bound ubisemiquinone but presumably iron-sulfur cluster N2.
IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients.
Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter.
Substance Name: Naltrexone
Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia.
Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study.
Cyclophosphamide for multiple sclerosis.
Progressive multiple sclerosis: The treatment gap.
The antiepileptic drug valproic acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis.
Genzyme receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) application
Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon.
Patients feeling severely affected by multiple sclerosis: How do patients want to communicate about end-of-life issues?
Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis.

Pages